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Abstract: Introduction: About 5% of visits to emergency departments are made up of conversion disorder cases. This
study was designed with the aim of comparing the effectiveness of quetiapine and haloperidol in controlling
conversion disorder symptoms. Methods: The present single-blind clinical trial has been performed on pa-
tients with conversion disorder (based on the DSM-IV definition) presenting to emergency department of 9-Day
Hospital, Torbat Heydariyeh, Iran, from January 2017 until May 2018. Results: 73 patients were allocated to
haloperidol and 71 to quetiapine group. Mean age of these patients was 32.03 ± 12.80 years (62.50% female).
Two groups were similar regarding the baseline characteristics. Within 30 minutes, 90.41% of haloperidol cases
and 91.55% of quetiapine cases were relieved (p=0.812). The most common side effects after 30 minutes were
extrapyramidal symptoms (9.59%) in the haloperidol group and fatigue and sleepiness (7.04%) in the quetiapine
group. Extrapyramidal symptoms was significantly higher than the quetiapine group (p=0.013). Conclusion:
The results of the present study showed that although quetiapine and haloperidol have a similar effect in reliev-
ing the patients from conversion disorder symptoms, the prevalence of extrapyramidal symptoms is significantly
lower in the group under treatment with quetiapine. Therefore, it seems that quetiapine is a safer drug compared
to haloperidol.
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1. Introduction
Conversion disorder is a type of disorder in physical func-
tion, which is not in conformity with anatomic and physio-
logic concepts of central or peripheral nervous system. This
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disorder occurs as a result of stress and helps alleviate the
stress of the patient. This disorder happens in various ages
and mostly in young women and individuals with a weakness
in coping mechanism (1). Conversion disorder is often asso-
ciated with simultaneous diagnosis of mood disorder, stress
disorder, and schizophrenia and its prevalence among the
relatives of those affected with these disorders is higher than
the general population (2). A significant symptom of these
disorders is involuntary loss of function or action disorder in
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the function of voluntary nervous system. Usually, the symp-
toms of this disease manifest suddenly and due to extreme
and exciting conditions; including numbness or paralysis in
hand and foot, fainting, etc. Sometimes the symptoms of
hysteria disappear at the same speed they were manifested
and they can usually be relieved or completely resolved via
suggestion (3). Statistics indicate that about 5% of visits to
emergency departments are made up of conversion disor-
der cases (4). There is no specific guideline for management
of these patients in the emergency department. Anti-stress
drugs lead to a decrease in stress of the patients and con-
sequently cause improvement in conversion disorders (4-6).
Haloperidol is a traditional anti-psychotic drug that is used
for treatment of various psychiatric disorders (7, 8). Better ef-
fectiveness of this drug compared to diazepam in treatment
of conversion disorder has been confirmed (9) but its side ef-
fects including extrapyramidal symptoms is a serious limita-
tion for its application (10, 11) and therefore, researchers are
looking for new drugs to replace it. Quetiapine is an atypi-
cal anti-psychotic drug used for treatment of schizophrenia,
bipolar disorder, and prescribed in association with an anti-
depressant drug for treatment of depression disorder. Effec-
tiveness of quetiapine in treating psychological disorders has
been witnessed, especially in mood and anxiety disorders
(12). This drug exerts its anti-psychotic effects via a direct
antagonistic effect on dopaminergic and serotonin receptors.
Therefore, it might be beneficial in treatment and control of
conversion disorders. The present study was designed with
the aim of comparing the effectiveness of quetiapine and
haloperidol in controlling conversion disorder symptoms in
patients presenting to the emergency department.
2. Methods
2.1. Study design and setting
The present single-blind clinical trial has been performed on
patients with conversion disorder in 9-Day Hospital, Torbat
Heydariyeh, Iran, from January 2017 until May 2018. Diag-
nosis of conversion disorder was done based on the 4th edi-
tion of Diagnostic and Statistical Manual of Mental Disor-
ders (DSM-IV- TR, 2000). Ethics committee of Torbat Hey-
dariyeh University of Medical Sciences approved the proto-
col of the present study. This clinical trial has been registered
on IRCT with following code: IRCT2015100712050N2. The
researchers adhered to the principles of Helsinki declaration
throughout the study period.
2.2. Participants
The studied participants included those affected with con-
version disorder diagnosed by an emergency medicine physi-
cian based on DSM-IV definitions. Exclusion criteria are
shown in table 1. Sampling was done via convenience
method. Patients who had one of the following conditions
were excluded from the study: no definite diagnosis of con-
version disorder, patients with problems in vital signs, crit-
ically ill patients, those aged under 18 years and over 60
years, pregnant and lactating patients, addicts, those not par-
ticipating or not tolerating oral medication, being affected
with acute cardiopulmonary, liver, or kidney diseases, his-
tory of Parkinson, history of epilepsy or taking anti-epileptic
drugs, history of hypothyroidism, hypokalemia, hypomagne-
semia, familial long QT syndrome, simultaneous treatment
with other neuroleptic drugs of drugs that elongate QT inter-
val, allergy to neuroleptic drugs and benzodiazepines.
2.3. Intervention
Patients underwent treatment with haloperidol or quetiap-
ine via block randomization with size 6 blocks (using a com-
puter program). IV haloperidol with 5mg dose (manufac-
tured by Caspian Company, Rasht, Iran) and rapid-releasing
oral quetiapine with 50 mg dose (manufactured by Tehran
Shimi, Tehran, Iran) were prescribed. The present study was
designed as a single-blind one in which the patient was blind
to the drug prescribed. Drugs were prepared as colorless and
anonymous packs and injected to the patients.
2.4. Outcome
The evaluated outcomes included being relieved from con-
version disorder symptoms and presentation of side effects.
Side effects were reported in 4 groups of extrapyramidal
symptoms, fatigue and sleepiness, headache, and other. Pa-
tients were evaluated 30 minutes and 24 hours after drug pre-
scription.
2.5. Data gathering
For gathering data, a pre-designed checklist consisting of de-
mographic data, history of mental diseases, symptoms on
admission, response to treatment, and side effects 30 min-
utes and 24 hours after treatment was used. An emergency
medicine specialist was responsible for data gathering.
2.6. Statistical Analysis
Sample size was calculated based on treatment success of
haloperidol (28%) and quetiapine (55%) in alleviating psy-
chotic symptoms (13). Therefore, considering α=0.05 and
β=0.1, the required sample size in each group was consid-
ered 68 patients. Data were analyzed via STATA 14.0 software
and with intention to treat analysis approach. Results were
reported as mean ± standard deviation or frequency and per-
centage. T-test was applied for comparing quantitative data,
and chi-square or Fisher’s exact tests were used to compare
the frequency between the 2 groups. In all analyses, p<0.05
was considered as level of significance.
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3. Results
3.1. Baseline characteristics of the patients
Throughout the study period, 144 patients were evaluated.
73 patients were allocated to haloperidol group and 71 pa-
tients were in the quetiapine group. Mean age of these pa-
tients was 32.03± 12.80 years and 62.50% of the patients were
female. Age (p=0.654) and sex (p=0.414) distribution were
not different between the 2 groups. 12 (16.44%) patients in
the haloperidol group and 6 (8.45%) patients in the queti-
apine group had a history of psychotic disorders (p=0.147).
The most common presentation of the patients on admis-
sion to emergency department were non-paralysis (25.69%)
and epileptic seizure (9.72%) (p=0.584). Table 1 depicts the
distribution of baseline characteristics of the patients in the
2 treatment groups.
3.2. Outcomes
Within 30 minutes after prescription of haloperidol and que-
tiapine, respectively, 90.41% and 91.55% of the patients in
each group were relieved of conversion disorder symptoms
(p=0.812). It should be noted that 30 minutes (p=0.412)
and 24 hours (p=0.940) after prescription of drugs the over-
all prevalence of side effects was not different between the
2 groups (table 2). The most common side effects after 30
minutes after prescription of the drugs were extrapyrami-
dal symptoms (9.59%) in the group under treatment with
haloperidol and fatigue and sleepiness (7.04%) in the group
treated with quetiapine (table 3). Analyses showed that
prevalence of extrapyramidal symptoms as side effects in
haloperidol group was significantly higher than the group
treated with quetiapine at this time (p=0.013). Although 24
hours after drug administration the prevalence of extrapyra-
midal symptoms in haloperidol group was still higher than
quetiapine group (8.22% vs. 1.41%), this difference was not
significant (p=0.116).
4. Discussion
The results of the present study showed that although que-
tiapine and haloperidol have a similar effect in relieving
the patients from conversion disorder symptoms, the preva-
lence of extrapyramidal symptoms is significantly lower in
the group under treatment with quetiapine. Therefore, it
seems that quetiapine is a safer drug compared to haloperi-
dol.
Effectiveness and safety of quetiapine have been evaluated
in controlling the symptoms of various mental diseases, but
to the best our knowledge, the role of this drug in control-
ling conversion disorder is evaluated in the present study
for the first time. However, there are studies available that
have assessed the effectiveness of quetiapine and haloperi-
dol in controlling the symptoms of other mental diseases.
For example Arvanitis et al. showed that quetiapine is su-
perior to haloperidol in 150 to 750 mg/day doses compared
to placebo and haloperidol in treating acute exacerbation of
schizophrenia (14). In addition, in their study, Velligan et al.
showed that quetiapine is more effective than haloperidol in
improving the cognitive function of schizophrenia patients
(15). However, Delmonte et al. showed that haloperidol is
more effective in treating severe mania compared to queti-
apine (16). Yet, Verachai et al. express that the effectiveness
and side effects of haloperidol and quetiapine in treatment of
methamphetamine-induced psychosis are similar (17). On
the other hand, Emsley et al. express that quetiapine has
both more effectiveness and less extrapyramidal side effects
in controlling the symptoms of schizophrenia compared to
haloperidol (18). As can be seen, the effectiveness of queti-
apine and haloperidol varies in treatment and control of dif-
ferent mental disease symptoms and there is a lot of disagree-
ment between the studies.
In one of the studies performed with the aim of compar-
ing prescription of quetiapine and venlafaxine in treating the
symptoms of somatization, it was determined that although
quetiapine leads to improvement of these symptoms, it has
a lower effectiveness compared to venlafaxine (19). In ad-
dition, Jin-long et al. showed that low doses of quetiapine
are effective in treatment of somatization disorder. The re-
searchers mentioned safety and rapid effect as the pros of
this drug (20). Since conversion disorder is one of the subsets
of somatization disorders it can be said that the 2 mentioned
studies are in line with the present study.
Quetiapine results in less extrapyramidal side effects com-
pared to haloperidol in controlling the effects of conversion
disorder. This is one of the strong points of this drug because
extrapyramidal symptoms are the most important side effect
that limits the use of haloperidol. Dyskinesia, dystonia, aki-
nesia, and neuroleptic malignant syndrome are among the
side effects that require emergency care (21) and if a drug is
available that reduces these symptoms, it will be very useful
in clinic. In the present study, only 1 case of extrapyramidal
side effects was observed in the quetiapine group, while there
were 13 patients who were affected by these side effects as a
result of consuming haloperidol. This significant difference
results in quetiapine being introduced as a proper replace-
ment for haloperidol.
5. Limitation
Among the limitations of the present study is the absence of
placebo arm. Since from an ethical point of view it is not pos-
sible to leave a group of patients untreated, this could not be
done. Among other limitations of this study was the short
duration of follow-up for the patients. Since the half-life of
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Table 1: Baseline characteristics of conversion disorder patients
Variable Haloperidol n=73 Quetiapine n=71 Total n=144 P
Age (mean, SD; years) 31.56±12.18 32.52±13.47 32.03±12.80 0.654
Sex (n, %)
Male 25 (34.25) 29 (40.85) 54 (37.50) 0.414
Female 48 (65.75) 42 (59.15) 90 (62.50)
Psychotic disorders’ History (n, %)
No 61 (83.56) 65 (91.55) 126 (87.50)
Yes 12 (16.44) 6 (8.45) 18 (12.5) 0.147
Presentation on admission (n, %)
Non-epileptic seizure 6 (8.22) 8 (11.27) 14 (9.72)
Speech disorder 8 (10.96) 4 (5.63) 12 (8.33) 0.584
Paralysis 17 (23.29) 20 (28.17) 37 (25.69)
Other 42 (57.53) 39 (54.93) 81 (56.25)
Table 2: Success of haloperidol and quetiapine in alleviating conversion disorder symptoms
Variable Haloperidol n=73 Quetiapine n=71 Total n=144 P
Response to treatment (n, %)
No 7 (9.59) 6 (8.45) 13 (9.03) 0.812
Yes 66 (90.41) 65 (91.55) 131 (90.97)
Side effect (n,%)
30 min
No 65 (89.04) 66 (92.96) 131 (90.97) 0.412
Yes 8 (10.96) 5 (7.04) 13 (9.03)
24 hours
No 64 (87.67) 62 (87.32) 126 (87.50) 0.950
Yes 9 (12.33) 9 (12.68) 18 (12.50)
Table 3: Comparison of haloperidol and quetiapine side effects in alleviating conversion disorder symptoms
Variable Haloperidol n=73 Quetiapine n=71 Total n=144 P*
30 min (n, %)
Extrapyramidal symptoms 7 (9.59) 0 (0.00) 7 (4.86) 0.013
Fatigue and sleepiness 3 (4.11) 5 (7.04) 8 (5.46) 0.491
Headache 2 (2.74) 1 (1.41) 3 (2.08) >0.999
Other 3 (4.11) 0 (0.00) 3 (2.08) 0.245
24 hours (n, %)
Extrapyramidal symptoms 6 (8.22) 1 (1.41) 7 (4.86) 0.116
Fatigue and sleepiness 6 (8.22) 6 (8.45) 12 (8.33) >0.999
Headache 2 (2.74) 2 (2.82) 4 (2.78) >0.999
Other 1 (1.37) 0 (0.00) 1 (0.69) >0.999
* , Based on Fisher’s exact test
haloperidol in body is 48 hours, 48-hour follow-up of the pa-
tients might present different results.
6. Conclusion
The results of the present study showed that although que-
tiapine and haloperidol have a similar effect in relieving
the patients from conversion disorder symptoms, the preva-
lence of extrapyramidal symptoms is significantly lower in
the group under treatment with quetiapine. Therefore, it
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